INTEREST 2016

Slideset

HIV

(Abstract) The effect of antiretroviral naïve HIV-1 infection on the ability of autologous NK cells to produce IFNg unpon exposure to Plasmodium falciparum- infected Erythrocytes | C. Sake Ngane

Slideset

HIV

(Abstract) Evaluating plasmatic biomarkers as disease signatures for the point of care monitoring of HIV-1 and comorbidities in resource limited regions | G. Nchinda

Slideset

HIV

(Abstract) Immune reconstitution and skewed responses after ART initiation in HIV I infected Ugandans | K. Nganou Makamdop

Slideset

HIV

(Abstract) HIV-1 group O infection in Cameroon from 2006 to 2013: prevalence, genetic diversity, evolution and public health challenges | A.F. Aghokeng

Slideset

HIV

(Abstract) Outcomes of second-line therapy in HIV positive adults attending for routine care at Yaoundé Central Hospital | A.O. Mafotsing Fopoussi

Slideset

HIV

Progress in Hepatitis B and C in sub-Saharan Africa | Magloire Biwole Sida, MD

Slideset

HIV

M-Health for HIV | Cees Hesp

Slideset

HIV

HIV Leadership and Financing Strategies for Countries in sub-Saharan Africa | Debrework Zewdie, PhD

Slideset

HIV

Where Do We Stand in 2016 | Andrew Hill, PhD

Slideset

HIV

Evolving Treatment Paradigms: Relevance in Resource- Limited Settings | Nicholas Paton, MD, FRCP

Slideset

HIV

Acquired Drug Resistance: Causes, Patterns, and Implications for SSA | Coumba Toure Kane, PharmD, PhD

Slideset

HIV

Progress on viral load monitoring, laboratory quality assurance, point of care | John Nkengasong, PhD

Slideset

HIV

Lessons learnt from Ebola Therapeutic Trials and Survivor Cohort Studies | Daouda Sissoko, MD

Slideset

HIV

Lessons learnt About Good Participatory Practices in Prevention and Treatment Trials for HIV and for Emerging Pathogens | Lillian Mutengu

Slideset

HIV

Lessons learnt About the Ethics of Trial Conduct in Emergency Settings | Morenike Ukpong Folayan

Slideset

HIV

Ebola to Lassa Fever: Leassons learnt | Ismail Adeshina Abdus-Salam

Slideset

HIV

HIV in Cameroon | Elat Nfetam Jean Bosco

Slideset

HIV

Progress in HIV Prevention and Treatment Scale-Up in Sub-Saharan Africa | Claire Mulanga

Slideset

HIV

The Joep Lange Institute / Art and Science in the HIV response | Brandon O’Dell

Slideset

HIV

HIV Testing Strategies: How to Reach 90% Knowledge of Serostatus (including the role of self-testing) | Elizabeth Marum

Slideset

HIV

Lessons learnt from Ebola Vaccine Trials in Emergency Settings | Godwin Enwere, MD, MSc

Slideset

HIV

Immediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts) | Roselyn Toby

Slideset

HIV

Knowing Your Data - Update on the Epidemiology of HIV in Children and Adolescents | Landry Tsague

Slideset

HIV

Insights and Lessons Learned on Retention, Adherence, and Achieving and Maintaining Viral Suppression: The Third 90 | Tsitsi Apollo

Slideset

HIV

Being Proactive - HIV Prevention in Adolescents | Magdalene Mayer

Slideset

HIV

Supporting Beyond Treatment - Care for HIV Positive Adolescents | Rama Diagne

Slideset

HIV

(Abstract) Decline in positivity rates among HIV-exposed infants with changes in PMTCT ARV regimens in Nigeria: evidence from 7 years of field implementation | H. Khamofu

Slideset

HIV

(Abstract) Favourable outcomes of paediatric second-line protease inhibitor-based antiretroviral treatment in Uganda | R.S. Boerma

Slideset

HIV

Transmitted Drug Resistance and First-line ART Treatment Outcomes in Ugandan Children | H. Mugerwa

Slideset

HIV

90-90-90 for all - Scale up of HIV Treatment for Adolescents | Victor Musiime, MBChB, MMED, PhD

Slideset

HIV

Formal Debate: Resolved that 90-90-90 Cannot be Attained | Affirming the motion | Mauro Schechter, MD, PhD

Slideset

HIV

(Abstract) Ultra-deep pyrosequencing of paediatric HIV-1 drug resistance and coreceptor suggests possible suitability of protease inhibitors and maraviroc at younger ages in Cameroon | J. Fokam

Slideset

HIV

Formal Debate: Resolved that 90-90-90 Cannot be Attained | Opposing the motion | Badara Samb, MD, PhD

Slideset

HIV

Formal Debate: Resolved that 90-90-90 Cannot be Attained | Affirming the motion | Isaac Tita

Slideset

HIV

(Abstract) Prevalence of non-infectious co-morbidities among HIV-positive subjects stably treated with tenofovir, lamivudine and ritonavir-boosted lopinavir in Cameroon | D. Fokom Victoire

Slideset

HIV

(Abstract) Current profile of dermatological diseases and events during HIV in Dakar | N.M.Dia

Slideset

HIV

(Abstract) Quality of life among HIV/AIDS patients on anti retro-viral therapy at Letlhakane primary hospital (Botswana): a cross sectional study | L. Kumboneki

Slideset

HIV

(Abstract) Model-based pediatric dosing of ritonavir-boosted Darunavir: an alternative to WHO guidelines | P. Mohammed

Slideset

HIV

(Abstract) Maximizing EID opportunities using the DBS Mentor Approach in Rural HIV Clinics in South-Eastern Nigeria | P. Anyanwu

Slideset

HIV

(Abstract) Getting pregnant in antiretroviral clinical trials: women choice and safety needs. Experience from the ANRS12169-2LADY and ANRS12286- MOBIDIP trials | A. Serris

Slideset

HIV

(Abstract) Retention in care among HIV-infected pregnant mothers on lifelong antiretroviral therapy (art) in Uganda | S. Muhumuza

Slideset

HIV

(Abstract) Immunologic Criteria are Poor Predictors of Virologic Outcomes: Implications for HIV Monitoring in a Large Treatment Program in Nigeria | J. Okuma

Slideset

HIV

(Abstract) Factors associated with virologic failure in HIV infected individuals in Mansa district, Zambia | G. Mutaawe

Slideset

HIV

Sustaining progress on scale-up of voluntary medical male circumcision (VMMC), including role of devices and early infant male circumcision | Zebedee Mwandi, MD

Slideset

HIV

Dolutegravir in contributing the 90:90:90 ambition | Tuna Lukiana MD, PhD

Slideset

HIV

New evidence on oral and topical PrEP for women: rings, gels, injectables | Nyaradzo Mgodi, MBChB, MMed

Slideset

HIV

Debate: Gilead: The Continent of Africa is Ready for HIV Pre-Exposure Prophylaxis (PreP) Implementation | Speaker for the Opposition | François Venter, MD, FCP, PhD

Slideset

HIV

Debate: Gilead: The Continent of Africa is Ready for HIV Pre-Exposure Prophylaxis (PreP) Implementation | Community Advocate | Stephen Watiti, MD

Slideset

HIV

(Abstract) Predictors of HIV-testing in South African adolescents: schools-based testing, pregnancy and sexual experience | C. Carty

Slideset

HIV

Trial, post-trial, & demonstration project results for Pre-exposure Prophylaxis (PrEP) | Elizabeth Irungu, MBChB, MPH

Slideset

HIV

(Abstract) EDCTP as a model for Europe-Africa partnership on HIV/AIDS research and capacity development: Examples from Cameroon | L.J. Pandya

Slideset

HIV

(Abstract) Tenofovir-containing first-line ART favourably reduce inflammation markers compared to thymidine analogue nucleoside reverse-transcriptase inhibitors | S. Kroeze

Slideset

HIV

(Abstract) Accumulation of HIV-1 drug resistance after continued virological failure on first-line antiretroviral therapy in adults and children | T.S.Boender

Slideset

HIV

Update on HIV vaccine strategies and trials: Active and passive immunization strategies | Hannah Kibuuka, MD

Slideset

HIV

Prevention Tools: Implementation and Discovery | Cissy Kityo, MD

Slideset

HIV

Sex work in sub-Saharan Africa | Isidore Traoré, MD, PhD

Slideset

HIV

Drug Use in sub-Saharan Africa: opportunities and challenges | Reychad Abdool, MD

Slideset

HIV

(Abstract) Finding the first 90% to achieve epidemic control | J. Masedza

Slideset

HIV

Men who have sex with men in sub-Saharan Africa | Iliassou Mfochive Njindam, MD, MPH

Slideset

HIV

(Abstract) Operational research studies among MSM in Cameroon: Linkage to treatment challenges | U. Tamoufe

Slideset

HIV

(Abstract) Pre-Clinical Evaluation of optimized Immunogens targeting the neutralizing epitopes in MPER of HIV envelope Glycoprotein

Slideset

HIV

INTEREST 2016

(Abstract) The effect of antiretroviral naïve HIV-1 infection on the ability of autologous NK cells to produce IFNg unpon exposure to Plasmodium falciparum- infected Erythrocytes | C. Sake Ngane

(Abstract) Evaluating plasmatic biomarkers as disease signatures for the point of care monitoring of HIV-1 and comorbidities in resource limited regions | G. Nchinda

(Abstract) Immune reconstitution and skewed responses after ART initiation in HIV I infected Ugandans | K. Nganou Makamdop

(Abstract) HIV-1 group O infection in Cameroon from 2006 to 2013: prevalence, genetic diversity, evolution and public health challenges | A.F. Aghokeng

(Abstract) Outcomes of second-line therapy in HIV positive adults attending for routine care at Yaoundé Central Hospital | A.O. Mafotsing Fopoussi

Progress in Hepatitis B and C in sub-Saharan Africa | Magloire Biwole Sida, MD

M-Health for HIV | Cees Hesp

HIV Leadership and Financing Strategies for Countries in sub-Saharan Africa | Debrework Zewdie, PhD

Where Do We Stand in 2016 | Andrew Hill, PhD

Evolving Treatment Paradigms: Relevance in Resource- Limited Settings | Nicholas Paton, MD, FRCP

Acquired Drug Resistance: Causes, Patterns, and Implications for SSA | Coumba Toure Kane, PharmD, PhD

Progress on viral load monitoring, laboratory quality assurance, point of care | John Nkengasong, PhD

Lessons learnt from Ebola Therapeutic Trials and Survivor Cohort Studies | Daouda Sissoko, MD

Lessons learnt About Good Participatory Practices in Prevention and Treatment Trials for HIV and for Emerging Pathogens | Lillian Mutengu

Lessons learnt About the Ethics of Trial Conduct in Emergency Settings | Morenike Ukpong Folayan

Ebola to Lassa Fever: Leassons learnt | Ismail Adeshina Abdus-Salam

HIV in Cameroon | Elat Nfetam Jean Bosco

Progress in HIV Prevention and Treatment Scale-Up in Sub-Saharan Africa | Claire Mulanga

The Joep Lange Institute / Art and Science in the HIV response | Brandon O’Dell

HIV Testing Strategies: How to Reach 90% Knowledge of Serostatus (including the role of self-testing) | Elizabeth Marum

Lessons learnt from Ebola Vaccine Trials in Emergency Settings | Godwin Enwere, MD, MSc

Immediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts) | Roselyn Toby

Knowing Your Data - Update on the Epidemiology of HIV in Children and Adolescents | Landry Tsague

Insights and Lessons Learned on Retention, Adherence, and Achieving and Maintaining Viral Suppression: The Third 90 | Tsitsi Apollo

Being Proactive - HIV Prevention in Adolescents | Magdalene Mayer

Supporting Beyond Treatment - Care for HIV Positive Adolescents | Rama Diagne

(Abstract) Decline in positivity rates among HIV-exposed infants with changes in PMTCT ARV regimens in Nigeria: evidence from 7 years of field implementation | H. Khamofu

(Abstract) Favourable outcomes of paediatric second-line protease inhibitor-based antiretroviral treatment in Uganda | R.S. Boerma

Transmitted Drug Resistance and First-line ART Treatment Outcomes in Ugandan Children | H. Mugerwa

90-90-90 for all - Scale up of HIV Treatment for Adolescents | Victor Musiime, MBChB, MMED, PhD

Formal Debate: Resolved that 90-90-90 Cannot be Attained | Affirming the motion | Mauro Schechter, MD, PhD

(Abstract) Ultra-deep pyrosequencing of paediatric HIV-1 drug resistance and coreceptor suggests possible suitability of protease inhibitors and maraviroc at younger ages in Cameroon | J. Fokam

Formal Debate: Resolved that 90-90-90 Cannot be Attained | Opposing the motion | Badara Samb, MD, PhD

Formal Debate: Resolved that 90-90-90 Cannot be Attained | Affirming the motion | Isaac Tita

(Abstract) Prevalence of non-infectious co-morbidities among HIV-positive subjects stably treated with tenofovir, lamivudine and ritonavir-boosted lopinavir in Cameroon | D. Fokom Victoire

(Abstract) Current profile of dermatological diseases and events during HIV in Dakar | N.M.Dia

(Abstract) Quality of life among HIV/AIDS patients on anti retro-viral therapy at Letlhakane primary hospital (Botswana): a cross sectional study | L. Kumboneki

(Abstract) Model-based pediatric dosing of ritonavir-boosted Darunavir: an alternative to WHO guidelines | P. Mohammed

(Abstract) Maximizing EID opportunities using the DBS Mentor Approach in Rural HIV Clinics in South-Eastern Nigeria | P. Anyanwu

(Abstract) Getting pregnant in antiretroviral clinical trials: women choice and safety needs. Experience from the ANRS12169-2LADY and ANRS12286- MOBIDIP trials | A. Serris

(Abstract) Retention in care among HIV-infected pregnant mothers on lifelong antiretroviral therapy (art) in Uganda | S. Muhumuza

(Abstract) Immunologic Criteria are Poor Predictors of Virologic Outcomes: Implications for HIV Monitoring in a Large Treatment Program in Nigeria | J. Okuma

(Abstract) Factors associated with virologic failure in HIV infected individuals in Mansa district, Zambia | G. Mutaawe

Sustaining progress on scale-up of voluntary medical male circumcision (VMMC), including role of devices and early infant male circumcision | Zebedee Mwandi, MD

Dolutegravir in contributing the 90:90:90 ambition | Tuna Lukiana MD, PhD

New evidence on oral and topical PrEP for women: rings, gels, injectables | Nyaradzo Mgodi, MBChB, MMed

Debate: Gilead: The Continent of Africa is Ready for HIV Pre-Exposure Prophylaxis (PreP) Implementation | Speaker for the Opposition | François Venter, MD, FCP, PhD

Debate: Gilead: The Continent of Africa is Ready for HIV Pre-Exposure Prophylaxis (PreP) Implementation | Community Advocate | Stephen Watiti, MD

(Abstract) Predictors of HIV-testing in South African adolescents: schools-based testing, pregnancy and sexual experience | C. Carty

Trial, post-trial, & demonstration project results for Pre-exposure Prophylaxis (PrEP) | Elizabeth Irungu, MBChB, MPH

(Abstract) EDCTP as a model for Europe-Africa partnership on HIV/AIDS research and capacity development: Examples from Cameroon | L.J. Pandya

(Abstract) Tenofovir-containing first-line ART favourably reduce inflammation markers compared to thymidine analogue nucleoside reverse-transcriptase inhibitors | S. Kroeze

(Abstract) Accumulation of HIV-1 drug resistance after continued virological failure on first-line antiretroviral therapy in adults and children | T.S.Boender

Update on HIV vaccine strategies and trials: Active and passive immunization strategies | Hannah Kibuuka, MD

Prevention Tools: Implementation and Discovery | Cissy Kityo, MD

Sex work in sub-Saharan Africa | Isidore Traoré, MD, PhD

Drug Use in sub-Saharan Africa: opportunities and challenges | Reychad Abdool, MD

(Abstract) Finding the first 90% to achieve epidemic control | J. Masedza

Men who have sex with men in sub-Saharan Africa | Iliassou Mfochive Njindam, MD, MPH

(Abstract) Operational research studies among MSM in Cameroon: Linkage to treatment challenges | U. Tamoufe

(Abstract) Pre-Clinical Evaluation of optimized Immunogens targeting the neutralizing epitopes in MPER of HIV envelope Glycoprotein

(Abstract) Identification of Rare HIV-1 Group N and HTLV-3 Strains in Rural South Cameroon | N. Ndembi